Compare fureasu Co., Ltd. with Similar Stocks
Dashboard
1
The company has declared positive results in Jan 70 after 5 consecutive negative quarters
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- NET PROFIT(Q) At JPY 123.51 MM has Grown at 509.06%
- ROCE(HY) Highest at 18.63%
2
With ROCE of -3.45%, it has a risky valuation with a 1.05 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,142 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.26
4.17%
1.10
Revenue and Profits:
Net Sales:
1,570 Million
(Quarterly Results - Dec 2025)
Net Profit:
116 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.36%
0%
6.36%
6 Months
5.83%
0%
5.83%
1 Year
18.47%
0%
18.47%
2 Years
-14.1%
0%
-14.1%
3 Years
0.47%
0%
0.47%
4 Years
-9.45%
0%
-9.45%
5 Years
-25.18%
0%
-25.18%
fureasu Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.86%
EBIT Growth (5y)
-207.20%
EBIT to Interest (avg)
5.93
Debt to EBITDA (avg)
3.76
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
1.79
Tax Ratio
72.52%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.49%
ROE (avg)
3.35%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.10
EV to EBIT
-30.52
EV to EBITDA
23.83
EV to Capital Employed
1.05
EV to Sales
0.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.45%
ROE (Latest)
-15.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,569.90
2,199.40
-28.62%
Operating Profit (PBDIT) excl Other Income
107.10
151.60
-29.35%
Interest
10.90
34.90
-68.77%
Exceptional Items
-8.30
20.00
-141.50%
Consolidate Net Profit
115.50
344.30
-66.45%
Operating Profit Margin (Excl OI)
68.20%
41.10%
2.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -28.62% vs -8.12% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -66.45% vs 586.30% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
7,582.60
5,710.00
32.80%
Operating Profit (PBDIT) excl Other Income
134.60
267.40
-49.66%
Interest
102.30
38.90
162.98%
Exceptional Items
-1.10
-4.80
77.08%
Consolidate Net Profit
-244.50
58.30
-519.38%
Operating Profit Margin (Excl OI)
-13.90%
19.40%
-3.33%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 32.80% vs 24.56% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -519.38% vs 84.49% in Mar 2024
About fureasu Co., Ltd. 
fureasu Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






